Cardinal Health Q1 revenue +10% to $54.8B; raises FY24 non-GAAP EPS guidance to $6.75-$7.00

CARDINAL HEALTH INC

2024-Q1 EPS reported $0.02 revenue$54,763,000,000

GAAP operating loss $14M due to $581M Medical goodwill impairment; GAAP diluted EPS $0.02.
Non-GAAP operating earnings $571M (+35%); non-GAAP diluted EPS $1.73 (+44%) vs. $1.20.
Pharmaceutical segment profit $507M (+18%); Medical segment profit $71M vs. ($8M) loss.
FY2024 non-GAAP EPS guidance raised to $6.75-$7.00 from $6.50-$6.75; pharma profit growth outlook raised to 7%-9%.
Interest and other expense guidance reduced to $100M-$120M; diluted shares ~249M.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CARDINAL HEALTH INC reported the quarter ended September 30, 2023 results: revenue $54.8 billion, net income $5 million, EPS $0.02. Guidance raised.

Period: the quarter ended September 30, 2023
Revenue: $54.8 billion
Net income: $5 million
EPS: $0.02
Guidance: raised
Result: reported results

Exact text from the filing

report. --- EX-99.1 (EX-99.1) --- FOR IMMEDIATE RELEASE Cardinal Health Reports First Quarter Fiscal 2024 Results and Raises Fiscal 2024 Outlook • Revenue increased 10% to $54.8 billion • GAAP 1 operating loss was $14 million and GAAP diluted EPS was $0.02, driven by a Medical segment goodwill impairment • Non-GAAP operating earnings increased 35% to $571

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

CARDINAL HEALTH INC filing history →

Source: SEC EDGAR

accession 0000721371-23-000083

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.